We asked 103 gastroenterologists in the U.S. for their opinion on the diagnosis and treatment of C. difficile infections (CDI).
Dr. Jessica Allegretti is the director of the fecal microbiota transplant program at Brigham and Women’s Hospital, and is leading several clinical trials investigating the use of fecal transplantation in chronic diseases such as IBD and Primary Sclerosing Cholangitis
- Who: 103 US-based gastroenterologists
- What: Diagnosis and treatment of C. difficile infections
- How: Recruited over 100+ GIs within 1 week to a qualitative nationwide survey
- What we discovered:
- 81% of GIs see up to 5 CDI patients a month.
- 71% of physicians identified that GDH reflexed to EIA testing is the recommended testing modality to diagnose CDI
- 57% of physicians currently offer FMT as a treatment option
- 83% of GIs plan to use microbiome-based therapeutics once approved in lieu of FMT.
Below is a detailed summary of responses to individual questions as well as anonymous comments from the KeyOps community.
Thank you for your valuable insights!